Newland Pharmaceutical Co., Ltd. (SHE:301277)
China · Delayed Price · Currency is CNY 10.10
-0.20 (-1.94%)
Sep 9, 2026, 4:00 PM EDT
Newland Pharmaceutical Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 706.3 | 662.81 | 720.99 | 643.85 | 621.21 | 508.93 |
Other Revenue | 4.25 | 9.57 | 5.44 | 7.59 | 6.15 | 4.91 |
| 710.55 | 672.38 | 726.44 | 651.44 | 627.36 | 513.84 | |
Revenue Growth | 3.20% | -7.44% | 11.51% | 3.84% | 22.09% | 18.63% |
Cost of Revenue | 498.44 | 447.24 | 437.43 | 392.84 | 404.01 | 307.82 |
Gross Profit | 212.11 | 225.14 | 289 | 258.6 | 223.36 | 206.02 |
Selling, General & Admin | 58.42 | 55.91 | 47.62 | 44.49 | 38.83 | 31.56 |
Research & Development | 34.01 | 46.18 | 55.49 | 51.96 | 30 | 20.59 |
Other Operating Expenses | 5.17 | 4.43 | 2.71 | 3.89 | 6.99 | 6.4 |
Operating Expenses | 98.8 | 105.66 | 108.1 | 96.75 | 78.04 | 69.69 |
Operating Income | 113.31 | 119.49 | 180.91 | 161.85 | 145.31 | 136.33 |
Interest Expense | -0.08 | -0.21 | -0.09 | -0.13 | -6.88 | -6.71 |
Interest & Investment Income | 9.26 | 10.94 | 16.7 | 19.63 | 1.34 | 0.26 |
Currency Exchange Gain (Loss) | -0.03 | -0.03 | 0.25 | 0.06 | 0.29 | -0.13 |
Other Non Operating Income (Expenses) | -2.3 | -0.02 | -0.06 | -0.12 | -0.09 | -0.06 |
EBT Excluding Unusual Items | 120.16 | 130.16 | 197.7 | 181.29 | 139.97 | 129.69 |
Gain (Loss) on Sale of Investments | 0.58 | 0.19 | -0.23 | 0.04 | 1.36 | 0.17 |
Gain (Loss) on Sale of Assets | 0.7 | - | - | 0.07 | -0.44 | -0.21 |
Asset Writedown | -10.72 | -1.49 | -2.62 | -1.46 | -0.32 | -0.11 |
Other Unusual Items | 5.05 | 5.26 | 2.5 | 1.22 | 2.31 | 2.4 |
Pretax Income | 115.77 | 134.12 | 197.35 | 181.16 | 142.88 | 131.94 |
Income Tax Expense | 13.56 | 14.06 | 24.34 | 23.96 | 11.17 | 17.11 |
Earnings From Continuing Operations | 102.21 | 120.07 | 173.01 | 157.2 | 131.71 | 114.82 |
Minority Interest in Earnings | 1.77 | 1.18 | 0.62 | 1.78 | 0.6 | 0.15 |
Net Income | 103.98 | 121.25 | 173.63 | 158.98 | 132.3 | 114.98 |
Net Income to Common | 103.98 | 121.25 | 173.63 | 158.98 | 132.3 | 114.98 |
Net Income Growth | -25.81% | -30.17% | 9.21% | 20.16% | 15.07% | -2.94% |
Shares Outstanding (Basic) | 393 | 391 | 395 | 391 | 302 | 294 |
Shares Outstanding (Diluted) | 393 | 391 | 395 | 391 | 302 | 294 |
Shares Change | 0.87% | -0.88% | 1.05% | 29.52% | 2.59% | 0.64% |
EPS (Basic) | 0.26 | 0.31 | 0.44 | 0.41 | 0.44 | 0.39 |
EPS (Diluted) | 0.26 | 0.31 | 0.44 | 0.41 | 0.44 | 0.39 |
EPS Growth | -26.45% | -29.54% | 8.08% | -7.22% | 12.17% | -3.36% |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 41.12 | 15.55 | 15.97 | 162.94 | 8.5 | 23.68 |
Free Cash Flow Per Share | 0.10 | 0.04 | 0.04 | 0.42 | 0.03 | 0.08 |
Dividend Per Share | 0.200 | 0.200 | 0.400 | 0.204 | 0.170 | - |
Dividend Growth | -50.00% | -50.00% | 95.98% | 19.99% | - | - |
Gross Margin | 29.85% | 33.48% | 39.78% | 39.70% | 35.60% | 40.09% |
Operating Margin | 15.95% | 17.77% | 24.90% | 24.85% | 23.16% | 26.53% |
Profit Margin | 14.63% | 18.03% | 23.90% | 24.40% | 21.09% | 22.38% |
Free Cash Flow Margin | 5.79% | 2.31% | 2.20% | 25.01% | 1.35% | 4.61% |
EBITDA | 173.7 | 172.06 | 216.31 | 190.69 | 167.38 | 157.19 |
EBITDA Margin | 24.45% | 25.59% | 29.78% | 29.27% | 26.68% | 30.59% |
D&A For EBITDA | 60.39 | 52.57 | 35.4 | 28.84 | 22.06 | 20.86 |
EBIT | 113.31 | 119.49 | 180.91 | 161.85 | 145.31 | 136.33 |
EBIT Margin | 15.95% | 17.77% | 24.90% | 24.85% | 23.16% | 26.53% |
Effective Tax Rate | 11.71% | 10.48% | 12.33% | 13.23% | 7.82% | 12.97% |
Revenue as Reported | 313.57 | 672.38 | 726.44 | 651.44 | 627.36 | 513.84 |
Advertising Expenses | - | 1.1 | 0.85 | 0.51 | 0.2 | 0.28 |